An evaluation of avelumab for the treatment of genitourinary tumors-Reference-Cited by-同舟云学术

An evaluation of avelumab for the treatment of genitourinary tumors

Published:2020-06-03 Issue:9 Volume:20 Page:971-979
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Stühler Viktoria¹,Maas Jan Moritz¹,Walz Simon¹,Stenzl Arnulf¹,Bedke Jens¹^ORCID

Affiliation:

1. Department of Urology, University of Tübingen, Tübingen, Germany

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2020.1769596

Reference64 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Surveillance E, And end results program. Cancer Stat Facts: kidney and renal pelvis cancer; [cited 2019 Mar 04]. Available from: https://seer.cancer.gov/statfacts/html/kidrp.html.

3. Systemic therapy in metastatic renal cell carcinoma

4. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral manifestation associated with avelumab;Oral Oncology Reports;2024-03

2. Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma;Frontiers in Public Health;2022-04-27

3. Dinitrophenol-mediated modulation of an anti-PD-L1 VHH for Fc-dependent effector functions and prolonged serum half-life;European Journal of Pharmaceutical Sciences;2021-10

4. Pembrolizumab for the treatment of renal cell carcinoma;Expert Opinion on Biological Therapy;2021-06-03